About This Reference Digest

What Peptide Research Protocols is

Peptide Research Protocols is an independent editorial reference digest covering the published research on three peptides studied in relation to the growth hormone axis: tesamorelin, MOTS-c and CJC-1295, with tesamorelin as the lead. The site exists to make a technically dense and frequently misrepresented literature accessible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which population or species, and how far that evidence genuinely reaches.

The three peptides were selected because they occupy distinct positions on the GH/IGF-1 axis research spectrum: tesamorelin has the most rigorous human trial record (an FDA-approved compound studied in Phase 3 RCTs) but a narrow approved indication; CJC-1295 has controlled human pharmacokinetic data but no efficacy trials and no approval; MOTS-c has compelling mechanistic and animal data but minimal human interventional evidence. Reading them together provides a structural map of how evidence accumulates in this field — and where it has not yet arrived.

Each compound has its own page with a plain-English summary, a mechanistic section, a research-findings section, a cautions section, and a contextual conclusion. A comparison page lines them up side by side. A shared references list aggregates every source.

How it is compiled

Three principles govern what appears here.

First, everything is anchored to the peer-reviewed literature. Every research claim is tied to a numbered citation from PubMed-indexed journal articles, reviews and regulatory monographs, with DOIs or PubMed links. Citations are listed in full on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such.

Second, the evidence is reported at its actual strength. Doses are described in the species and route in which they were studied — for example, subcutaneous 2 mg/day in HIV-infected adults or intraperitoneal in mice — never scaled to humans or offered as a recommendation. Where evidence is preclinical, single-species or rests on a pharmacokinetic study rather than an efficacy trial, the page says so plainly. Where an approved indication is narrow, the boundary is kept in view, not quietly elided.

Third, the three pages are cross-referenced. Because shared themes — pituitary GHRH signalling, IGF-1 axis activation, metabolic regulation — recur across all three compounds, the pages link to one another so a reader can follow a mechanism from one context to the next.

What it is not

Peptide Research Protocols is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions or prescribe anything. It does not recommend a dose, schedule or route of administration for any person.

The peptides discussed here range from a prescription-only pharmaceutical approved for a specific indication (tesamorelin) to research chemicals with no approved use at all (MOTS-c, CJC-1295). None is presented here as a general-purpose supplement or wellness compound. Readers interested in any condition described in the underlying research should consult a licensed clinician operating within their own jurisdiction, working with regulated, evidence-based options. The value this digest offers is a calm, accurate map of the published literature — nothing more, and nothing it pretends to be.